<DOC>
	<DOCNO>NCT02242773</DOCNO>
	<brief_summary>1 . Multiparametric MRI ultrasound ( MRIus ) -guided direct MRI-guided biopsy allow direct sampling tumor compartment distinct multiparametric-MRI ( MP-MRI ) characteristic , term habitat , increase rate `` progression '' early ( first second ) surveillance biopsy decrease rate `` progression '' late ( third ) surveillance biopsy compare historic transrectal ultrasound ( TRUS ) -guided biopsy rate . 2 . Identifying high risk tumor early reduce proportion patient poor response delay primary treatment . 3 . Radiomics signatures MP-MRI define pattern associate progression . 4 . Genomic signature base RNA tumor tissue define pattern associate habitat radiomics signature , well progression .</brief_summary>
	<brief_title>The Miami MAST Trial</brief_title>
	<detailed_description>Single arm therapeutic trial investigate impact MRI MRI-US fusion biopsy identify high grade volume tumor early good selection patient active surveillance improve outcome undergo delay treatment initial observation.. MRI-US fusion biopsy include target suspicious area see MRI well segment sample remain gland . Patients undergo MRI MRI-US fusion biopsy within 3 month enrollment trial repeat MRI-US fusion biopsy every year assess overall rate temporal distribution progression . Serum , urine prostate biopsy tissue serially collect investigate association various molecular biomarkers radiologic histological progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Biopsy confirm adenocarcinoma prostate within 18 month prior enrollment ; 2 . Preenrollment prostate biopsy must consist least 8 core ; 3 . Biopsy review University Miami Pathologist ; 4 . Serum ProstateSpecific Antigen ( PSA ) ≤ 20 ng/ml within 3 month study enrollment ; 5 . Age ≥ 35 ≤ 85 year ; 6 . Ability understand willingness sign write informed consent document ; 7 . Patients must agree undergo serial multiparametric MRI MRIguided biopsy ; 8 . Patients must agree fill longitudinal psychosocial questionnaire assess health relate quality life . 1 . Greater 4 core positive , Gleason score , University Miami ( UM ) review , 2 . Greater 2 core positive Gleason 3+4 cancer , 3 . Gleason 4+3 high cancer single biopsy core . 4 . Extracapsular extension suspect digital rectal exam confirmation MRI . Suspicion extracapsular extension MRI alone exclusion study enrollment . 5 . Subject candidate multiparametric MRI contrast . Some reason may include ( limited ) : renal insufficiency , foreign body pacemaker . 6 . No prior pelvic radiotherapy . 7 . No prior surgery prostate , transurethral procedure benign prostatic hyperplasia ( e.g. , transurethral resection , green light laser treatment ) . 8 . No concurrent , active malignancy , nonmetastatic skin cancer type , superficial bladder cancer , early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) &lt; stage IV follicular lymphoma . If prior malignancy remission ≥ 3 year patient eligible . 9 . Bilateral hip replacement .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Active Surveillance</keyword>
	<keyword>MRI-Guided Biopsy</keyword>
	<keyword>Multi-parametric MRI</keyword>
	<keyword>MP-MRI</keyword>
</DOC>